

**Jammu and Kashmir Cancer Screening Consortium
(Preventive Oncology Initiative)
Charter**

Preamble: The Cancer Screening Consortium (JKCSC) is established by Dr. Mufti's Oncopathology and Clinical Reference Laboratory in collaboration with medical oncologists, surgical oncologists, ENT surgeons, radiologists, geneticists, gastroenterologists, gynaecologists, urologists, psycho-oncologists, preventive medicine specialists and other healthcare workers. The primary objective of the consortium is to foster and implement comprehensive cancer screening programs aimed at early detection and diagnosis of the most common cancers. The JKCSC recognizes the imperative role of proactive screening in reducing cancer-related mortality and improving patient outcomes.

I. Objectives:

1. **Screening Programs:** Develop, promote, and execute evidence-based screening programs for prevalent cancers, adhering to established national and international guidelines.
2. **Early Diagnosis:** Facilitate early diagnosis through accessible and timely screening methods, emphasizing the importance of detecting cancer at its nascent stage.
3. **Virtual Tumor Board:** Establish and maintain a virtual tumor board for multidisciplinary discussions on diagnosed cancer cases. This platform will facilitate collaborative decision-making among oncologists, radiologists, pathologists, and other specialists for optimal treatment planning.

II. Cancer Statistics in India:

The consortium acknowledges the rising trend in cancer incidence in India and the associated challenges. As per current statistics, the anticipated increase in cancer cases over the coming years necessitates a proactive approach towards screening and early intervention. Addressing this surge in cancer incidence requires a concerted effort from the healthcare community.

III. Importance of Screening:

1. **Early Intervention:** Early detection through systematic screening enables timely initiation of treatment, significantly improving prognosis and reducing treatment complexity.
2. **Cost-effectiveness:** Screening programs contribute to cost-effective healthcare by identifying cancers at an earlier, more treatable stage, thereby reducing the financial burden on patients and the healthcare system.
3. **Public Health Impact:** Implementation of screening programs can lead to a substantial reduction in cancer-related morbidity and mortality, positively impacting the overall public health landscape.

IV. Guidelines and Standard Operating Procedures (SOPs):

The JKCSO commits to strictly adhere to established cancer screening guidelines and SOPs, ensuring the highest quality and uniformity in screening practices. Regular updates and reviews will be conducted to align with evolving scientific knowledge and advancements in cancer research.

V. Collaboration and Training:

The consortium encourages collaboration among its members and seeks to enhance the knowledge and skills of healthcare professionals through continuous education and training programs focused on cancer screening and early diagnosis.

VI. Ethical Considerations:

All activities undertaken by the JKCSO will prioritize patient confidentiality, informed consent, and ethical considerations. The consortium members commit to upholding the highest standards of integrity and professionalism in their endeavors.

VII. Funding and Resources:

The consortium will actively seek funding and resources to support its initiatives, collaborating with governmental bodies, non-profit organizations, and the private sector to ensure the sustainability and scalability of its programs.

VIII. Periodic Evaluation:

The JKCSO will conduct regular evaluations of its screening programs, incorporating feedback from stakeholders and utilizing performance metrics to continuously enhance the effectiveness and efficiency of its initiatives.

IX. Membership Invitation: Join the Cancer Screening Consortium for a Collective Impact

The Cancer Screening Consortium (CSC) extends an invitation to professionals and members of civil society dedicated to making a transformative impact in the realm of cancer prevention, detection, and treatment. As a member, you will be an integral part of a multidisciplinary alliance comprising oncopathologists, medical oncologists, surgical oncologists, radiologists, geneticists, psycho-oncologists, healthcare workers, and preventive medicine specialists.

Professional Members: Professionals in the fields of oncology, pathology, radiology, genetics, and related disciplines are invited to contribute their expertise to the consortium's initiatives. By joining the CSC, you will have the opportunity to actively participate in shaping evidence-based screening programs, engaging in virtual tumor board discussions, and contributing to the advancement of cancer research and early diagnosis practices.

Civil Society Members: Civil society plays a crucial role in raising awareness, advocating for policy changes, and supporting community outreach. We welcome individuals and organizations passionate about cancer prevention and early detection to join us. As a civil society member, you will have the chance to actively participate in awareness campaigns, community education programs, and collaborate with healthcare professionals to promote the importance of cancer screening.

By becoming a member of the Cancer Screening Consortium, you align yourself with a collective effort dedicated to addressing the growing challenges posed by the increasing incidence of cancer in India. Together, we can make a meaningful impact on public health, fostering a future where early cancer detection is the norm rather than the exception.

To join the Cancer Screening Consortium, please visit contact us at mufti.suhail@oncopathlab.com. Together, let's shape a healthier future for our communities.

The Cancer Screening Consortium is committed to making a substantial impact on cancer outcomes by promoting early detection and diagnosis. Through collaborative efforts and adherence to established guidelines, the consortium aims to contribute significantly to reducing the burden of cancer on individuals, families, and society at large.

Signed: Dr. Mufti and Members of the Cancer Screening Consortium

04-02-2024



Dr Mufti's
Oncopathology
& Clinical Reference Laboratory
Precision Diagnostics, Compassionate Care